Epigenomics Ag Stock Buy Hold or Sell Recommendation
| EPGNF Stock | USD 0.79 0.00 0.00% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Epigenomics AG is 'Strong Sell'. Macroaxis provides Epigenomics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding EPGNF positions.
Check out Epigenomics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Epigenomics and provide practical buy, sell, or hold advice based on investors' constraints. Epigenomics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Epigenomics |
Execute Epigenomics Buy or Sell Advice
The Epigenomics recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Epigenomics AG. Macroaxis does not own or have any residual interests in Epigenomics AG or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Epigenomics' advice using the current market data and latest reported fundamentals.
Time Horizon
30 Days |
Risk Tolerance
I am an educated risk taker |
 |  |
Not Rated
Epigenomics Trading Alerts and Improvement Suggestions
| Epigenomics AG generated a negative expected return over the last 90 days | |
| Epigenomics AG has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 6.2 M. Net Loss for the year was (2.43 M) with profit before overhead, payroll, taxes, and interest of 6.07 M. | |
| Epigenomics AG has accumulated about 15.77 M in cash with (4.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 35.0% of the company shares are held by company insiders |
Epigenomics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Epigenomics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Epigenomics' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Epigenomics pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
Epigenomics Volatility Alert
At this time Epigenomics AG exhibits very low volatility. Epigenomics AG is a potential penny stock. Although Epigenomics may be in fact a good instrument to invest, many penny pink sheets are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Epigenomics AG. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Epigenomics instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Epigenomics Fundamentals Vs Peers
Comparing Epigenomics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Epigenomics' direct or indirect competition across all of the common fundamentals between Epigenomics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Epigenomics or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Epigenomics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Epigenomics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Epigenomics to competition |
| Fundamentals | Epigenomics | Peer Average |
| Return On Equity | -0.38 | -0.31 |
| Return On Asset | -0.24 | -0.14 |
| Operating Margin | (15.90) % | (5.51) % |
| Current Valuation | (9.71 M) | 16.62 B |
| Shares Outstanding | 4.09 M | 571.82 M |
| Shares Owned By Insiders | 35.00 % | 10.09 % |
| Shares Owned By Institutions | 4.86 % | 39.21 % |
| Price To Earning | (8.47) X | 28.72 X |
| Price To Book | 0.39 X | 9.51 X |
| Price To Sales | 10.64 X | 11.42 X |
| Revenue | 6.2 M | 9.43 B |
| Gross Profit | 6.07 M | 27.38 B |
| EBITDA | (1.94 M) | 3.9 B |
| Net Income | (2.43 M) | 570.98 M |
| Cash And Equivalents | 15.77 M | 2.7 B |
| Cash Per Share | 0.96 X | 5.01 X |
| Total Debt | 966 K | 5.32 B |
| Debt To Equity | 0.07 % | 48.70 % |
| Current Ratio | 3.88 X | 2.16 X |
| Book Value Per Share | 3.41 X | 1.93 K |
| Cash Flow From Operations | (4.15 M) | 971.22 M |
| Earnings Per Share | (0.30) X | 3.12 X |
| Target Price | 8.59 | |
| Number Of Employees | 36 | 18.84 K |
| Beta | 1.08 | -0.15 |
| Market Capitalization | 6.01 M | 19.03 B |
| Total Asset | 24.66 M | 29.47 B |
| Retained Earnings | (62 M) | 9.33 B |
| Working Capital | 5 M | 1.48 B |
| Current Asset | 10 M | 9.34 B |
| Current Liabilities | 5 M | 7.9 B |
| Z Score | 0.8 | 8.72 |
| Net Asset | 24.66 M |
Epigenomics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Epigenomics . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Epigenomics Buy or Sell Advice
When is the right time to buy or sell Epigenomics AG? Buying financial instruments such as Epigenomics Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Epigenomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Asset Allocation ETFs Thematic Idea Now
Asset Allocation ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Asset Allocation ETFs theme has 156 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Asset Allocation ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Epigenomics Pink Sheet
Epigenomics financial ratios help investors to determine whether Epigenomics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Epigenomics with respect to the benefits of owning Epigenomics security.